{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:41:47Z","timestamp":1793421707348,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.eplepsyres.2022.106994","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T12:06:12Z","timestamp":1659441972000},"page":"106994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Anti-epileptogenic effects of synaptic vesicle protein 2A modulation in a mouse model of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"186","author":[{"given":"Juliana C.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel C.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2022.106994_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119910","article-title":"Early onset of hypersynchronous network activity and expression of a marker of chronic seizures in the Tg2576 mouse model of Alzheimer's disease","volume":"10","author":"Bezzina","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eplepsyres.2022.106994_bib2","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1111\/epi.12993","article-title":"A mouse model of Alzheimer's disease displays increased susceptibility to kindling and seizure-associated death","volume":"56","author":"Chan","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.106994_bib3","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","article-title":"Assessing synaptic density in alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","article-title":"Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice","volume":"274","author":"Hsiao","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.eplepsyres.2022.106994_bib5","doi-asserted-by":"crossref","first-page":"20119","DOI":"10.1038\/srep20119","article-title":"Interictal spikes during sleep are an early defect in the Tg2576 mouse model of beta-amyloid neuropathology","volume":"6","author":"Kam","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1517\/17460441.2.11.1537","article-title":"Levetiracetam: the first SV2A ligand for the treatment of epilepsy","volume":"2","author":"Klitgaard","year":"2007","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng0195-21","article-title":"The Alzheimer\u2019s A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice","volume":"9","author":"LaFerla","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib8","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1111\/epi.14435","article-title":"Chronic fluoxetine treatment accelerates kindling epileptogenesis in mice independently of 5-HT2A receptors","volume":"59","author":"Li","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.106994_bib9","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/bjp.2008.198","article-title":"Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein SV2A","volume":"254","author":"Matagne","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib10","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/alz.12097","article-title":"In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET","volume":"16","author":"Mecca","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib11","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1523\/JNEUROSCI.5215-08.2009","article-title":"Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy","volume":"29","author":"Minkeviciene","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib12","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/j.1460-2075.1996.tb00468.x","article-title":"Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice","volume":"15","author":"Moechars","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13195-015-0110-9","article-title":"Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer\u2019s disease mouse model","volume":"7","author":"Nygaard","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","article-title":"Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer\u2019s disease","volume":"55","author":"Palop","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.eplepsyres.2022.106994_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","article-title":"Modification of seizure activity by electrical stimulation. II. Motor seizure","volume":"32","author":"Racine","year":"1972","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib16","doi-asserted-by":"crossref","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","article-title":"Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer\u2019s disease model","volume":"109","author":"Sanchez","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.eplepsyres.2022.106994_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jfma.2015.08.004","article-title":"A systematic review of familial Alzheimer\u2019s disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences","volume":"115","author":"Shea","year":"2016","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib18","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.2967\/jnumed.118.223867","article-title":"In vivo synaptic density imaging with (11)C-UCB-J detects treatment effects of saracatinib in a mouse model of alzheimer disease","volume":"60","author":"Toyonaga","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.eplepsyres.2022.106994_bib19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaneurol.2021.3310","article-title":"Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial","volume":"78","author":"Vossel","year":"2021","journal-title":"JAMA Neurol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122001450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122001450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:47:07Z","timestamp":1760276827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121122001450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":19,"alternative-id":["S0920121122001450"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106994","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-epileptogenic effects of synaptic vesicle protein 2A modulation in a mouse model of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106994"}}